Appeal No. 1997-3945
Application No. 08/410,390
inter alia, a toxin (page 4, lines 1 through 3). Goodwin's
system includes (1) the biotinylated compound (page 3, line 50
through page 4, line 28); (2) an avidin-containing binding
protein capable of localizing selectively at the target site,
when administered parenterally (page 4, line 30 through page
5, line 20); and (3) a clearing agent (page 5, lines 25
through 35). The avidin-containing binding protein serves
both as a targeting agent capable of localizing specifically
at an internal target site, and as an agent for binding the
biotinylated compound to the target site through the avidin-
biotin interaction. The binding protein may be, for example,
a monoclonal antibody (page 5, lines 5 through 14).
Goodwin further discloses a method for targeting a
therapeutic or diagnostic agent to a selected internal body
site, e.g., a solid tumor, by sequentially administering the
avidin-containing binding protein; the clearing agent; and the
biotinylated compound. In the passage at page 5, lines 50
through 52, Goodwin makes clear that these components are
administered sequentially:
According to an important advantage of the
method, the binding protein is delivered in non-
complexed form, i.e., without bound biotinylated
-8-
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007